Ann: Positive AD-214 Phase I extension study results, page-104

  1. 5,514 Posts.
    lightbulb Created with Sketch. 684
    Great interview.

    Yes, lowest deals start at an up front payment of US$40m with milestone payments afterwards can be upwards to $1b.

    Thats an upfront payment equivalent to 11c/ share . As I said yesterday I’m expecting at least 12-15c rise in sp given the milestone payments on top and the pipeline of other opportunities. Probably going to be looking at a AU$80m plus Market Cap minimum on US$40m upfront. But this is looking to be a very safe and effective drug. The offer could be like the one that Syndax received and be almost 4 times that up front.

    He also mentioned conversation is well advanced with suitable partners. Games will be played with shares next few weeks for accumulation . But with more than one major Biotech looking at this you would think offers should come in quickly.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.2¢
Change
0.000(0.00%)
Mkt cap ! $2.225M
Open High Low Value Volume
0.2¢ 0.3¢ 0.2¢ $11.25K 5.461M

Buyers (Bids)

No. Vol. Price($)
10 12795213 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 16667741 19
View Market Depth
Last trade - 15.59pm 25/07/2025 (20 minute delay) ?
1AD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.